Aim: To investigate the effect of glucocorticoids on brown adipose tissue (BAT) function in humans.
| INTRODUCTION
Glucocorticoids are widely used to treat many immune and inflammatory conditions. Obesity is a common adverse effect of glucocorticoid excess. 1 The mechanism of glucocorticoid-induced obesity is poorly understood, but is probably multifactorial. There is evidence that glucocorticoids stimulate differentiation of preadipocytes into mature white adipocytes 2, 3 and appetite. 4, 5 In animals, glucocorticoids impair brown adipose tissue (BAT) function, predisposing them to obesity. [6] [7] [8] There is a paucity of information on the effect of glucocorticoids on BAT function in humans. We have previously demonstrated in vitro that glucocorticoids inhibit the response of cultured human brown adipocytes to adrenergic stimulation. 9 Ramage et al. have recently reported that glucocorticoids acutely stimulate BAT function, 10 an effect that is against the obesogenic effect of glucocorticoids.
BAT protects against hypothermia and obesity by dissipating energy as heat in response to cold exposure and food intake. This thermogenic property is conferred by uncoupling protein-1 (UCP1) which uncouples substrate oxidation from ATP synthesis. 11 It was previously believed that, in humans, BAT was present only during infancy. However, over the last decade, there is strong evidence that functional BAT persists and is highly prevalent in adult life. [12] [13] [14] [15] [16] There is also cumulating evidence that BAT plays a significant role in energy and substrate metabolism. 17 Energy is produced from the oxidation of substrates to sustain mammalian life. 18 Chemical energy (ATP) and heat are 2 different forms of energy that constitute the total energy produced during substrate oxidation; ATP is the energy form useful to perform body functions, 18 while heat is the energy wasted in the presence of active UCPs. 19 Changes in either or both forms influence total energy production. Cold exposure and food intake stimulate energy production.
In the case of cold exposure, increased thermogenesis from UCP-rich tissues such as BAT mostly accounts for the increase in total energy production. 19 In contrast, the stimulation of energy production following a meal arises from a combined contribution from BAT thermogenesis and the energy required for processing and storage of nutrients. [19] [20] [21] [22] Total energy production is usually quantified by indirect calorimetry, based on gas exchange. 18 In order to specifically determine the thermogenic contribution after a meal, an independent method for assessing heat is required. Infrared thermography is a valuable and reliable method for assessing the thermogenic activity of human BAT, both in vitro 23, 24 and in vivo. [25] [26] [27] [28] [29] In this randomized double-blind placebo-controlled cross-over study, we investigated the effect of treatment with prednisolone for 1 week on BAT function, with a focus on its thermogenic contribution to postprandial metabolism in humans by combining metabolic imaging, infrared thermography and indirect calorimetry. 
| MATERIALS AND METHODS

| Subjects
| Study design
This was a randomized, double-blind, placebo-controlled cross-over study, involving 1 week each of oral prednisolone treatment (15 mg once daily at~0700-0800 AM) and matching placebo with an intervening 2-week wash-out period ( Figure 1A ). Study assessments were conducted over 2 consecutive days at the end of each treatment, in temperature-controlled rooms (19 C) ( Figure 1B ). BAT metabolic activity was assessed by FDG-PET-CT scan. BAT thermogenic response to cold and to meal intake was assessed by measuring skin temperatures overlying the supraclavicular (SCL) BAT depots using infrared thermography. Postprandial energy and substrate metabolism was assessed after a standardized mixed meal by indirect calorimetry and blood tests. Subjects were advised to avoid exercise and alcohol for 24 hours prior to study assessment and to avoid coffee on the days of study assessment.
| Randomization and masking
Research staff (2 individuals) not involved in the study prepared numbered medication envelopes, each containing 2 bottles (1 bottle containing active study medication and 1 bottle containing placebo, marked as treatment 1 or 2) using 1:1 randomization (half of the packs containing placebo as treatment 1 and half containing active medication as treatment 1), and kept the list of treatment sequences in a locked cabinet. Blinded investigators randomly assigned the prepacked medication envelopes to participants and recorded the envelope numbers in a study log. Participants and investigators were masked to the treatment assignment sequence throughout the study.
| FDG-PET-CT scan
Subjects fasted for at least 5 hours, changed to standard hospital gowns and rested comfortably in a recliner chair in an air-conditioned room cooled to 19 C for a total of 3 hours prior to the PET-CT scan.
75 MBq (2 mCi) of 
| Infrared thermography (IRT)
To assess BAT thermogenic response, an infrared imaging camera (FLIR B425, 3.1Mpixel, FLIR Systems Australia Pty Ltd, Melbourne, Australia) was used to acquire thermal images of the anterior neck and upper chest regions as previously described. 29 Subjects were seated upright, and the camera was positioned with a tripod, at 1 m from the subject at the level of the neck. 29 Images were taken at 0, 1 and 2 hour(s) of cooling before PET-CT scanning, and at 0, 1 and 2 hour(s) after ingestion of a standardized meal (n = 11) ( Figure 1B ).
Baseline temperature measurement for the cold exposure study was taken at 23 to 24 C, and that for the meal study was taken after 60 minutes in the temperature-controlled room at 19 C.
Thermogenic response to the meal was assessed under the same temperature-controlled conditions as for the FDG-PET study. Using 
| Indirect calorimetry
Resting metabolic rate (RMR) and substrate metabolism were quantified after an overnight 10-hour fast by indirect calorimetry using a metabolic monitor (ParvoMedics, Sandy, Utah), which was calibrated against standard gases before each study, as previously described. 30, 31 Subjects rested for 30 minutes in a supine position in the temperature-controlled room (19 C) before measuring RMR over 20 minutes. Meal-induced energy production rate was measured at 30 to 60 minutes and at 90 to 120 minutes after a standardized meal.
Energy production rates (EPR), carbohydrate oxidation (Cox) and fat oxidation (Fox), and lipid synthesis rates (LSR) were calculated using the equations described by Ferrannini 18 and Frayn where N = 0.14 × body weight kg/1440. 
| Blood tests
| Standardized meal
For the meal study, subjects consumed a mixed meal drink (Ensure plus, Abbott Nutrition; 237 mL; 355 kcal consisting of 56% carbohydrate, 29% fat, 15% protein) within 5 minutes, followed by a small amount of water.
| Statistical analysis
Statistical analysis was performed using IBM SPSS Software Version 
| RESULTS
Plasma ACTH was undetectable (< 10 ng/L) in all participants during prednisolone treatment as compared to 21 AE 2.3 ng/L during placebo (P < .01), confirming that participants adhered to treatment.
| BAT metabolic activity
The metabolic activity of SCL BAT depots was quantified by FDG- 
| BAT thermogenic response
The thermogenic response of BAT was assessed by measuring skin temperatures overlying the SCL BAT depots at 0, 1 and 2 hour(s) of cooling (19 C), and after a standardized mixed meal drink (Ensure plus).
During the 2 hours of cooling, SCL skin temperature (averaged for left and right SCL) decreased (Table 1 ). The magnitude of decrease was significantly greater during prednisolone treatment (P < .01) ( Figure 3A ), indicating that prednisolone suppresses the thermogenic response of BAT to cooling.
Postprandially, SCL skin temperature rose during placebo, but fell during prednisolone treatment (P = .02) ( Figure 3B ) (Table 1) , suggesting that prednisolone inhibits the thermogenic response of BAT to a meal. 
| Relationship between metabolic and thermogenic response
To ascertain whether the temperature response to the meal is attributed to BAT, we first compared meal-induced SCL temperature changes between subjects who were PET-positive and those who were PET-negative (defined using SUV threshold of 2) during the placebo phase. Before the meal, the mean SCL temperature was not significantly different between PET-positive and PET-negative subjects (33.2 AE 0.27 C vs 33.0 AE 0.12 C; P = .2). After the meal, the mean SCL temperature rose to a significantly higher level in PET-positive than in PET-negative subjects (33.65 AE 0.11 vs 33.05 AE 0.11 C; P = .01). This observation provides evidence that SCL temperature changes reflect heat produced from underlying BAT depots that are metabolically active.
The reduction in SCL temperature induced by prednisolone at 1 hour after the meal correlated positively with the reduction in BAT metabolic activity on FDG-PET-CT (r = 0.65, P = .03). On the other hand, the changes in skin temperatures of the control chest area during cooling (P = .1) and after the meal (P = .3) did not differ significantly between placebo and prednisolone treatment ( Table 1) . The mean temperatures after the meal were significantly different between the SCL and chest regions (P = .036) during placebo and prednisolone treatments. Thus, prednisolone specifically reduced SCL but not chest skin temperature, indicating that SCL temperature changes were unlikely to be the result of factors such as changes in skin blood flow or subcutaneous tissue thickness. Together, these results provide strong evidence that prednisolone inhibits the thermogenic activity of BAT.
| Postprandial energy production and substrate metabolism
After determining that prednisolone reduced the dissipation of energy as heat from BAT, we next analysed the effect of prednisolone on total energy production and substrate metabolism in response to the mixed meal using indirect calorimetry and blood tests. In the fasting state, the serum FFAs level was significantly higher (0.32 AE 0.07 vs 0.44 AE 0.05 mmol/L; P = .04) during prednisolone treatment, consistent with known metabolic effects of glucocorticoids. . Representative thermograms of a subject during placebo and prednisolone treatment in response to cold (C) and to a meal (D). Yellow dots represent markers that were applied over the proximal, mid and distal clavicles to identify SCL regions in the thermograms. Results are expressed as mean AE SEM. *P < .05, **P < .01 using repeated measures ANOVA −23.7 AE 4.9 mg/min; P = .03) and rise in Cox (+80.2 AE 9.7 vs +110.5 AE 16.1 mg/min; P = .01). The mean insulin concentration during prednisolone treatment (21.8 AE 7 mU/L) was approximately 50%
higher than that with placebo (14 AE 2.9 mU/L); however, the difference was not statistically significant (P = .06). Among the 13 subjects, Table 1 ). The data from 1 subject was excluded because of wide fluctuations caused by unstable gas exchange.
The increase in LSR at 1 hour after the meal was significantly higher (P = .03) during prednisolone treatment ( Figure 4B ). The increase in EPR correlated significantly with the enhancement in LSR induced by prednisolone (r = 0.6, P = .02) ( Figure 4C ). These results indicate that the rise in EPR after the meal likely reflects the energy required for lipid synthesis, and that prednisolone drives the energy towards storage, while reducing the wastage as heat after nutrient intake.
| Catecholamines
As the sympathetic nervous system (SNS) plays a central role in stimulating the activity of BAT and thermogenesis, 11 we explored whether the SNS is involved in the modulation of BAT activity and thermogenesis by glucocorticoids. We measured plasma NA concentrations during the meal study. There was no significant difference in baseline fasting levels between the placebo and prednisolone treatments. In the 4 subjects from whom paired blood samples were The current findings extend our in vitro observation that dexamethasone attenuates the stimulation by isoprenaline of UCP1 FIGURE 4 Effect of glucocorticoids on energy metabolism after a mixed meal. Prednisolone enhanced meal-induced energy production rate (EPR) a (A) and lipid synthesis rate (LSR) b (B). There was a significant positive relationship between prednisolone-induced increases in EPR and LSR after the meal c (C). Results are expressed as mean AE SEM. *P < .05, **P < .01 using a repeated measures ANOVA, b paired t-test and c Pearson's correlation (n = 12) expression and oxygen consumption in human brown adipocytes. 9 Our findings are in line with the results of animal studies. In rodents, glucocorticoids reduce the expression of UCP1 6 and tissue responsiveness to adrenergic and cold stimulations. 6, 35 On the other hand, depletion of glucocorticoids by adrenalectomy 36, 37 or inhibition of their action by mifepristone, a glucocorticoid receptor antagonist, 38, 39 stimulates BAT and reduces weight gain.
In contrast, Ramage et al. 10 recently reported that glucocorticoids acutely enhanced BAT function in humans over and above the stimulatory effect of acute cold exposure, an observation that cannot explain the obesogenic effect of glucocorticoids. FDG uptake and skin temperatures overlying SCL BAT increased after 2 doses of prednisolone administered over 12 hours. In our study, glucocorticoids inhibited BAT activity after 1 week. It is probable that the effect of glucocorticoids on BAT is time-dependent. Indeed, in in vitro studies of brown adipocytes, cortisol stimulated UCP1 expression in the first 24 hours but inhibited this after 48 hours. 10 In a retrospective analysis of patients undergoing PET-CT, the investigators also observed active BAT to be less prevalent among patients undergoing chronic glucocorticoid treatment. 10 These observations collectively point to a time-dependent dominant inhibitory effect of glucocorticoids on BAT.
Glucocorticoids may act directly or indirectly on BAT. Glucocorticoids bind to both glucocorticoid (GR) and mineralocorticoid (MR) receptors. 40 Our in vitro study employing dexamethasone, a selective agonist for GR, suggests a direct action on GRs. 9 This is supported by another in vitro finding that MR antagonists did not affect the inhibition of BAT by cortisol. 10 In vivo, BAT is regulated mainly by the SNS via the release of NA, 11 and there is evidence that plasma NA concentration is a good indicator of SNS activity.
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The post-prandial fall in NA during prednisolone treatment, in contrast to the rise observed during placebo treatment in the 4 subjects, suggests that glucocorticoids may also act indirectly via the SNS to suppress BAT. However, given the limited number of blood samples, this preliminary finding needs to be confirmed in future studies.
BAT protects animals against diet-induced obesity by dissipating nutrient energy as heat. Therefore, an important aim of our study was to determine the effect of glucocorticoids on the contribution of BAT to energy metabolism in response to nutrient intake.
FDG-PET cannot be used to assess BAT response to nutrients because of the competing effect of meal-derived glucose with FDG uptake. We, therefore, employed IRT to assess BAT thermogenesis.
We found that prednisolone inhibited the postprandial rise in temperature overlying the SCL BAT depots, and the prednisoloneinduced reduction in SCL temperature response highly correlated with a parallel reduction in the BAT FDG uptake. In addition, significant changes in temperatures during prednisolone therapy occurred for skin overlying the SCL BAT depots but not over a control chest area. Together, these findings provide strong evidence that glucocorticoids inhibit the thermogenic response of BAT to both cooling and meal intake.
We next assessed whole body energy and substrate metabolism in response to a meal. Prednisolone enhanced the EPR following a meal. The energy produced after a meal consists of 2 components, that the cost of digestion and absorption was negligible. 42 On the other hand, the energy cost of storage is high, amounting to 24% of the energy content of glucose for conversion to fat. 20 From indirect calorimetry, we found strong evidence that prednisolone enhanced postprandial lipid synthesis as indicted by an RQ >1. The meal-induced increase in EPR is commonly referred to as 'diet-induced thermogenesis (DIT)'. Employing separate methods to assess energy metabolism and heat, we have shown that the mealinduced increase in EPR measured by indirect calorimetry does not FIGURE 5 Schematic representation of the components of energy production after a meal and the effect of glucocorticoids. The total energy produced after a meal comprises 2 components: 1) the energy required for nutrient processing and storage, and 2) the energy dissipated as heat by uncoupling protein (UCP) containing tissues such as brown adipose tissue (BAT). Glucocorticoids enhance total energy production after a meal, increasing proportionately the component for storage as fat while suppressing the component of wastage as heat necessarily represent thermogenesis. The use of the term 'DIT' to describe the energy produced after a meal can be conceptually misleading, because thermogenesis infers energy dissipated as heat. Our findings, along with those of others, 21, 22 show that EPR after a meal is affected by the anabolic fate of nutrients such as lipogenesis.
Reporting the meal-induced increase in EPR as an enhancement of 'DIT' would have conveyed, incorrectly, that glucocorticoids stimulate heat dissipation, a desirable metabolic outcome favouring weight loss.
In fact, glucocorticoids inhibited thermogenesis, increasing the proportion of nutrient energy for lipid synthesis.
Our observations shed light on the long-standing controversy concerning a pathogenic role of 'DIT' in obesity. 47, 48 As the mealinduced EPR or 'DIT' quantified by indirect calorimetry can vary, depending on contributions from its 2 components, differences in 'DIT' between individuals may not necessarily reflect corresponding differences in heat dissipation after the same meal. It is conceivable that the assumed attribution to thermogenesis by indirect calorimetry underlies the controversial evidence surrounding the role of 'DIT' in obesity.
There is increasing evidence that BAT contributes significantly to adiposity and substrate metabolism in humans. 17 Increase in BAT activity has led to fat loss of approximately 0.7 kg over 6 weeks, 49 amounting to approximately 6 kg over 12 months, and improvements in glycaemic status 50 and insulin sensitivity over 4 to 6 weeks. 51, 52 The observed 50% reduction in BAT activity induced by 15 mg/d prednisolone may translate into a gain in fat mass of approximately 3 kg per year. This is metabolically significant and clinically relevant,
given the widespread use of glucocorticoids and the rising tide of obesity in all communities, and the fact that the dose is in the range commonly used in clinical practice.
In summary, 1-week treatment with prednisolone suppresses BAT metabolic activity and thermogenesis, while stimulating mealinduced energy production and lipogenesis. We conclude that prolonged exposure to glucocorticoids suppresses human BAT function, diverting energy from dissipation as heat towards storage as fat after nutrient intake. Our findings suggest a role of BAT in the interplay between heat and nutrient metabolism in the regulation of energy balance. We provide novel mechanistic insights into the obesogenic effect of glucocorticoids, underscoring the metabolic importance of BAT in human energy metabolism.
